Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Rohan C Parikh"'
Autor:
Olulade Ayodele, Rohan C. Parikh, Elizabeth Esterberg, Mayank Ajmera, Bridgett Goodwin, James Williams, Nirav K. Desai, David A. Katzka
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 5, Pp 659-670 (2024)
Background and Aims: Limited real-world nontertiary care evidence on the patient therapeutic journey and disease burden of eosinophilic esophagitis (EoE) exists. The aim was to collect real-world data on the EoE patient journey across different age g
Externí odkaz:
https://doaj.org/article/08c7ec01ad574d75aed08691639226d9
Autor:
Elias Obeid, Rohan C. Parikh, Elizabeth Esterberg, Bhakti Arondekar, Abigail Hitchens, Lillian Shahied Arruda, Alexander Niyazov, Kristen Whitaker
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
AimTo examine clinical characteristics, real-world treatment patterns, and health outcomes among patients with germline BRCA1/2-mutated, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer (ABC).MethodsA retrospective an
Externí odkaz:
https://doaj.org/article/87cee8aa415a4c878d1bef57e7b50c16
Autor:
Pedram Razavi, Rohan C Parikh, Barbara Acevedo, Abigail Hitchens, Mehnaj Ahmed, Anton Safonov, Emanuela Ferraro, Komal Jhaveri, Michelle Sidel, Stacey Simmons, Mark Robson, Sarat Chandarlapaty, Sanjeev Balu
Publikováno v:
Cancer Research. 82:P1-18
Background: Oncogenic mutations involving PIK3CA gene (PI3Kα) are observed in over 40% of patients with hormone receptor-positive (HR+) advanced breast cancer (ABC). Clinical efficacy of PI3K inhibition was demonstrated in a recent trial, but data o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6eb3d9d9d649ab635eb8503581b5c76e
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-18
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-18
Autor:
Joyce O'Shaughnessy, Steven Paulson, Lorraine Brisbin, James Lindsey, Anna Williford, Monica Lisi, Rohan C. Parikh, Stacey Simmons, Sanjeev Balu
Publikováno v:
Cancer Research. 82:P5-13
Background: Alpelisib (PIQRAY®) in combination with fulvestrant was approved by the US- FDA in May of 2019 for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) PIK3CA mutant advanced or meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53c5c6f23573ed0ce2b1350720dcdc20
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-16
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-16
Autor:
Naleen Raj Bhandari, Lisa M Hess, Rohan C Parikh, Anthony N Sireci, Peter M Krein, James A Kaye
Publikováno v:
Personalized Medicine.
Aim: To describe real-world testing patterns for RET in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. Materials & methods: The authors performed a ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27251595b9e349e83cdd379db4cdb7f2
https://doi.org/10.2217/pme-2022-0050
https://doi.org/10.2217/pme-2022-0050
Autor:
Elias Obeid, Rohan C Parikh, Elizabeth Esterberg, Bhakti Arondekar, Abigail Hitchens, Lillian Shahied Arruda, Alexander Niyazov
Publikováno v:
Cancer Research. 81:PS11-42
Background: gBRCA1/2mut represents~5% of ABC. Recently poly ADP-ribose polymerases inhibitors (PARPi) have demonstrated improved clinical outcomes, advantageous side effect profile, and favorable patient reported outcomes vs. chemotherapy(CT) in gBRC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdce4606fe54bf40e0360a4c2354a55c
https://doi.org/10.1158/1538-7445.sabcs20-ps11-42
https://doi.org/10.1158/1538-7445.sabcs20-ps11-42
Autor:
Maria Diez-Campelo, Aylin Yucel, Ravi K. Goyal, Rohan C. Parikh, Elizabeth Esterberg, Maria Jimenez, Martina Sluga-O'Callaghan, Dimana Miteva, Hong Xiao, Ulrich Germing
Publikováno v:
Blood. 140:13308-13309
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f44c2a01b3434203d31b6fa9460dd77
https://doi.org/10.1182/blood-2022-156411
https://doi.org/10.1182/blood-2022-156411
Autor:
Francesco Passamonti, Florian H Heidel, Rohan C Parikh, Mayank Ajmera, Derek Tang, Jose Alberto Nadal, Keith L Davis, Pranav Abraham
Aim: To assess real-world ruxolitinib treatment patterns and outcomes in patients diagnosed with primary or secondary myelofibrosis. Materials & methods: Patient medical records were reviewed in six countries. Results: Eligible patients (n = 469) had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dee0e0a1bb53b9c018c0c30dc4f7069
http://hdl.handle.net/11383/2137170
http://hdl.handle.net/11383/2137170
